Vaxil Bio (TSXV:VXL) ROCE % : 11.88% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Vaxil Bio ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vaxil Bio's annualized ROCE % for the quarter that ended in Dec. 2023 was 11.88%.

Vaxil Bio ROCE % Historical Data

The historical data trend for Vaxil Bio's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxil Bio ROCE % Chart

Vaxil Bio Annual Data

Trend

May14

May15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-1,161.21

-78.75

-41.18

-25.56

Vaxil Bio Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-56.77	-46.60	-53.56	-15.11	11.88

Vaxil Bio ROCE % Calculation

Vaxil Bio's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.259	/	( ( (1.541 - 0.405)	+	(0.976 - 0.085) )	/ 2 )
	=	-0.259	/	( (1.136	+	0.891)	/ 2 )
	=	-0.259	/	1.0135
	=	-25.56 %

Vaxil Bio's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	0.104	/	( ( (1.05 - 0.19)	+	(0.976 - 0.085) )	/ 2 )
	=	0.104	/	( ( 0.86	+	0.891 )	/ 2 )
	=	0.104	/	0.8755
	=	11.88 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Vaxil Bio (TSXV:VXL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vaxil Bio ROCE % Related Terms

Thank you for viewing the detailed overview of Vaxil Bio's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxil Bio (TSXV:VXL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxil Bio Ltd (TSXV:VXL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

VXLLF:USA

Address

C/O Kira Lynn, Bennet Jones LLP, 3400 One First Canadian Place, Toronto, ON, CAN, M5X 1A4

Website

https://www.vaxil-bio.com

Vaxil Bio Ltd is an Israeli immunotherapy biotech company focused on a novel drug discovery and development platform based on Signal Peptides which the company deploys to fight infectious diseases and cancer.

Executives

Gadi Levin

Director, Senior Officer

Vaxil Bio (TSXV:VXL) Headlines

No Headlines